67,501 Shares in Novo Nordisk A/S $NVO Bought by FFG Partners LLC

FFG Partners LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 67,501 shares of the company’s stock, valued at approximately $2,481,000. Novo Nordisk A/S makes up 1.0% of FFG Partners LLC’s holdings, making the stock its 22nd largest holding.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the last quarter. Capital International Investors raised its holdings in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Boston Partners bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $310,199,000. Price T Rowe Associates Inc. MD boosted its position in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the topic of several research analyst reports. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. Finally, Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday. Five investment analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s oral Wegovy is gaining attention after UK approval, a development that could expand access to its weight-loss treatment and strengthen its position in the fast-growing GLP-1 market. Novo Nordisk (NVO) Stock Surges 6.55% on Oral Wegovy UK Approval
• Positive Sentiment: A South Africa court barred a pharmacy group from selling compounded semaglutide products, which may help Novo Nordisk protect demand for its branded Ozempic and related GLP-1 medicines. South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case
• Positive Sentiment: Analyst-style coverage highlighted Novo Nordisk as a leading longevity and anti-aging stock, reinforcing investor optimism around long-term demand for its obesity and diabetes portfolio. Here is why Novo Nordisk A/S (NVO) is among the Best Longevity and Anti-Aging Stocks to Buy
• Neutral Sentiment: A separate article noted Novo Nordisk shares have been volatile this year; while the stock has recovered recently, the company still faces a large gap between the current share price and some long-term valuation estimates. A Look at Novo Nordisk AS (NVO) After 6.2% Gain — GF Value $144.58 vs Price $45.88
• Negative Sentiment: Novo Nordisk is also dealing with a reported data breach investigation, which could raise operational, legal, and reputational risks if sensitive research or trial information was compromised. Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
• Negative Sentiment: Commentary on Novo Nordisk’s Wegovy pill also emphasized a more complicated competitive picture, suggesting rivals may still challenge the company’s market share despite strong launch momentum. Novo Nordisk’s Wegovy pill headlines mask complicated competitive reality

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $45.90 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $71.79. The firm has a market cap of $204.94 billion, a PE ratio of 10.77, a price-to-earnings-growth ratio of 3.86 and a beta of 0.78. The business has a 50 day moving average price of $43.09 and a 200-day moving average price of $45.82.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Equities research analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.